BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27659012)

  • 21. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Curcumin downregulates p38 MAPK-dependent X-ray repair cross-complement group 1 (XRCC1) expression to enhance cisplatin-induced cytotoxicity in human lung cancer cells.
    Tung CL; Jian YJ; Chen JC; Wang TJ; Chen WC; Zheng HY; Chang PY; Liao KS; Lin YW
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):657-66. PubMed ID: 27026405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.
    Ko JC; Su YJ; Lin ST; Jhan JY; Ciou SC; Cheng CM; Chiu YF; Kuo YH; Tsai MS; Lin YW
    Lung Cancer; 2010 Aug; 69(2):155-64. PubMed ID: 19962780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.
    Jiang HG; Chen P; Su JY; Wu M; Qian H; Wang Y; Li J
    J Cell Physiol; 2017 Dec; 232(12):3433-3443. PubMed ID: 28075014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
    Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1.
    Deng WG; Wu G; Ueda K; Xu K; Roth JA; Ji L
    Cancer Gene Ther; 2008 Jan; 15(1):29-39. PubMed ID: 17828283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-107 regulates cisplatin chemosensitivity of A549 non small cell lung cancer cell line by targeting cyclin dependent kinase 8.
    Zhang Z; Zhang L; Yin ZY; Fan XL; Hu B; Wang LQ; Zhang D
    Int J Clin Exp Pathol; 2014; 7(10):7236-41. PubMed ID: 25400821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
    Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
    Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer.
    Zhao J; Fu W; Liao H; Dai L; Jiang Z; Pan Y; Huang H; Mo Y; Li S; Yang G; Yin J
    BMC Cancer; 2015 Oct; 15():731. PubMed ID: 26482648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
    Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
    PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-small and small cell lung carcinoma cell lines exhibit cell type-specific sensitivity to edelfosine-induced cell death and different cell line-specific responses to edelfosine treatment.
    Shafer SH; Williams CL
    Int J Oncol; 2003 Aug; 23(2):389-400. PubMed ID: 12851688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cisplatin-induced downregulation of SOX1 increases drug resistance by activating autophagy in non-small cell lung cancer cell.
    Li N; Li X; Li S; Zhou S; Zhou Q
    Biochem Biophys Res Commun; 2013 Sep; 439(2):187-90. PubMed ID: 23994634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC.
    Ryan SL; Beard S; Barr MP; Umezawa K; Heavey S; Godwin P; Gray SG; Cormican D; Finn SP; Gately KA; Davies AM; Thompson EW; Richard DJ; O'Byrne KJ; Adams MN; Baird AM
    Lung Cancer; 2019 Sep; 135():217-227. PubMed ID: 31446998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance.
    Brozovic A; Fritz G; Christmann M; Zisowsky J; Jaehde U; Osmak M; Kaina B
    Int J Cancer; 2004 Dec; 112(6):974-85. PubMed ID: 15386344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Wilms' tumor 1 enhances Cisplatin-resistance of advanced NSCLC.
    Wu C; Wang Y; Xia Y; He S; Wang Z; Chen Y; Wu C; Shu Y; Jiang J
    FEBS Lett; 2014 Dec; 588(24):4566-72. PubMed ID: 25447528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1.
    Ma Y; Li X; Cheng S; Wei W; Li Y
    Mol Med Rep; 2015 Jan; 11(1):625-32. PubMed ID: 25339370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ABCG2 regulates the pattern of self-renewing divisions in cisplatin-resistant non-small cell lung cancer cell lines.
    Tang Y; Hou J; Li G; Song Z; Li X; Yang C; Liu W; Hu Y; Xu Y
    Oncol Rep; 2014 Nov; 32(5):2168-74. PubMed ID: 25200103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment.
    Gatti L; Cossa G; Tinelli S; Carenini N; Arrighetti N; Pennati M; Cominetti D; De Cesare M; Zunino F; Zaffaroni N; Perego P
    J Pharmacol Exp Ther; 2014 Mar; 348(3):360-71. PubMed ID: 24345465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin.
    Lee MW; Kim DS; Min NY; Kim HT
    Int J Cancer; 2008 May; 122(10):2380-4. PubMed ID: 18224693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Downregulation of TFAM inhibits the tumorigenesis of non-small cell lung cancer by activating ROS-mediated JNK/p38MAPK signaling and reducing cellular bioenergetics.
    Xie D; Wu X; Lan L; Shangguan F; Lin X; Chen F; Xu S; Zhang Y; Chen Z; Huang K; Wang R; Wang L; Song X; Liu Y; Lu B
    Oncotarget; 2016 Mar; 7(10):11609-24. PubMed ID: 26820294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.